Étude pour évaluer l'efficacité, l'innocuité et la tolérabilité de l'IMU-838 chez les patients atteints de sclérose en plaques récurrente (ENSURE-1)
Une étude de phase 3 multicentrique, randomisée et en double aveugle pour évaluer l'efficacité, l'innocuité et la tolérabilité de l'IMU-838 par rapport au placebo chez les adultes atteints de sclérose en plaques récurrente (ENSURE-1)
Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This study will be a multicenter, randomized, double-blind, placebo-controlled study with a blinded Main Treatment Period (MT) and an Open Label Period (OLE) to evaluate the efficacy, safety, and tolerability of IMU-838 in adult patients with RMS. The study will consist of the following periods:
Screening Period: Approximately 28 days Main Treatment Period: Up to 72 weeks (approximately 15 months) Open Label Extension Period: Up to approximately 8 years
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Tirana, Albanie, 1005
- Klinika Mjekesore Nuova, Neurology Clinic
-
Tirana, Albanie
- Hygeia Hospital Tirana
-
-
-
-
-
Algiers, Algérie, 16000
- University Hospital Center Mustapha Pacha, Algiers
-
Annaba, Algérie, 23000
- University Hospital Center Ibn Sina, Annaba
-
Oran, Algérie, 31000
- University Hospital Center of Oran
-
-
-
-
-
Münster, Allemagne, 48149
- University Hospital Muenster, Institute Translational Neurology dept. Neurology
-
-
-
-
-
Blagoevgrad, Bulgarie, 2700
- MHAT Puls AD
-
Burgas, Bulgarie, 8000
- MHAT "Heart and Brain", EAD
-
Pleven, Bulgarie, 5800
- MC Exacta Medica OOD
-
Pleven, Bulgarie, 5800
- MHAT Avis Medica
-
Pleven, Bulgarie, 5800
- UMHAT Dr.Georgi Stranski EAD
-
Pleven, Bulgarie
- Heart and Brain University Hospital
-
Pleven, Bulgarie
- MC Vita 1
-
Plovdiv, Bulgarie, 4002
- UMHAT Sveti Georgi
-
Plovdiv, Bulgarie, 4001
- UMHAT "Kaspela"EOOD
-
Plovdiv, Bulgarie, 4002
- UMHAT "Pulmed" Ltd
-
Rousse, Bulgarie
- UMHAT "Medica Ruse"
-
Sofia, Bulgarie, 1431
- UMHAT "Alexandrovska"
-
Sofia, Bulgarie, 1431
- UMHAT "Alexandrovska" EAD
-
Sofia, Bulgarie
- Military Medical Academy
-
Sofia, Bulgarie, 1606
- Military Medical Academy MHAT
-
Sofia, Bulgarie, 1000
- CCB Medical Institute Ministry of Interior
-
Sofia, Bulgarie, 1000
- Diagnostic and Consultative Center Neoclinic
-
Sofia, Bulgarie, 1000
- UMHAT "Sveti Ivan Rilski" EAD
-
Sofia, Bulgarie, 1113
- MHATNP "Sveti Naum", EAD
-
Sofia, Bulgarie, 1113
- MHATNPsy Sveti Naum EAD
-
Sofia, Bulgarie, 1618
- MHAT "Sveta Sofia" EOOD
-
Sofia, Bulgarie
- UMHAT"Tsaritsa Yoanna -ISUL
-
Sofia, Bulgarie
- UMHATEM N.Pirogov
-
Varna, Bulgarie
- UMHAT "Sveta Marina" EAD, First Clinic of Neurological Diseases
-
-
-
-
-
Tbilisi, Géorgie
- LTD Aversi Clinic
-
Tbilisi, Géorgie, 0141
- 1st Uni Clinic of Tbilisi LEPL
-
Tbilisi, Géorgie
- Eristavi Experimental Center
-
Tbilisi, Géorgie
- J.S.C. Curatio Clinic
-
Tbilisi, Géorgie
- Khechinashvili University Hospital
-
Tbilisi, Géorgie
- LTD New Hospitals
-
Tbilisi, Géorgie
- MediClub Georgia LLC
-
Tbilisi, Géorgie
- Sarajishvili Neurology Institute
-
Tbilisi, Géorgie
- JSC "Jerarsi"
-
Tbilisi, Géorgie
- Pineo Medical Ecosystem LTD
-
-
-
-
-
Bangalore, Inde, 560092
- Medstar Speciality Hospital
-
Mangalore, Inde, 575002
- Mallikatte, Kadri
-
Nagpur, Inde
- Jasleen Hospital
-
New Delhi, Inde, 110060
- Sir Ganga Ram Hospital
-
Pune, Inde, 411001
- Ruby Hospital
-
Shimla, Inde, 171006
- Atal Institute of Medical Super Specialities (AIMSS)
-
Varanasi, Inde, 221005
- Institute of Medical Sciences Banaras Hindu University,IMS BHU Varanasi
-
-
-
-
-
Amman, Jordan, 11942
- Jordan University Hospital
-
Amman, Jordan, 11196
- Istiklal Hospital
-
Amman, Jordan
- TSH Advanced Clinical Center
-
Irbid, Jordan
- Irbid Speciality Hospital
-
-
-
-
-
Beirut, Liban
- Hotel Dieu de France Hospital
-
Hamra, Liban, 1107-2020
- AUB Medical Center
-
-
-
-
-
Kaunas, Lituanie, 50161
- Lietuvos Sveikatos Mokslu Universitetas - Kauno Klinikos
-
-
-
-
-
Skopje, Macédoine du Nord
- Hospital "8 mi Septemvri"
-
Skopje, Macédoine du Nord
- University Clinic of Neurology
-
-
-
-
-
Culiacán, Mexique, 80020
- Neurociencias Estudios Clínicos S.C
-
Guadalajara, Mexique, 44670
- Instituto Jalisciense de Metabolismo, SC
-
Mexico City, Mexique, 14050
- Unidad de Investigación en Salud de Chihuahua S.C.
-
Mexico City, Mexique
- Clinstile SA de CV
-
Mexico City, Mexique, 03310
- Grupo medico camino SC
-
Mexico City, Mexique, 06700
- Consultorio Médico Expert Brain Clinic
-
Morelia, Mexique, 58000
- Centro de Morelia
-
Veracruz, Mexique, 91900
- Sociedad de Metabolismo y Corazon, S.C.
-
Veracruz, Mexique, 91900
- Faicic de RL de CV
-
-
-
-
-
Chisinau, Moldavie
- Instititute of Emergency Medicine
-
Chisinau, Moldavie
- Medico-Sanitary Public Institution, Institute of Neurology and Neurosurgery "Diomid Gherman"
-
Chisinau, Moldavie
- The Diomid Gherman Institute of Neurology and Neurosurgery
-
-
-
-
-
Nikšić, Monténégro
- General Hospital Niksic
-
Podgorica, Monténégro
- Clinical Center of Montenegro
-
-
-
-
-
Lublin, Pologne, 20-064
- NZOZ Neuromed M. i M. Nastaj Sp. P.
-
-
-
-
-
Barnaul, Russie, 656045
- City Hospital #5, Barnaul
-
Barnaul, Russie, 656906
- Profimed LLC
-
Bryansk, Russie, 241033
- Bryansk Regional Hospital 1
-
Chelyabinsk, Russie, 454021
- Regional Clinical Hospital 3
-
Krasnoyarsk, Russie, 660037
- Federal Siberian Scientific and Clinical Centre of Federal Medical and Biological Agency
-
Kursk, Russie, 305007
- Kursk Regional Clinical Hospital
-
Nizhny Novgorod, Russie, 603076
- Medis LLC
-
Novosibirsk, Russie, 630004
- Sibneiromed LLC
-
Novosibirsk, Russie, 630007
- SDMCH SDMC of FMBA of Russia
-
Perm, Russie, 614045
- Perm State Medical University n.a. Acad. E. A. Vagner
-
Samara, Russie, 443095
- Samara regional clinical hospital n. a. V. L. Seredavin
-
Yekaterinburg, Russie, 620102
- Sverdlovsk Regional Clinical Hospital #1
-
-
-
-
-
Chernihiv, Ukraine, 14029
- Communal Non-Commercial Enterprise "Chernihiv Regional Hospital",Department of Neurology
-
Chernivtsi, Ukraine, 58023
- Regional Municipal Non-commercial Enterprise "Chernivtsi Emergency Medical Hospital"
-
Chernivtsi, Ukraine
- Chernihiv Regional Hospital
-
Ivano-Frankivsk, Ukraine, 76008
- Regional Clinical Hospital
-
Ivano-Frankivsk, Ukraine, 76493
- Neuro Global, LLC
-
Khmelnytskyi, Ukraine
- Khmelnytsky regional hospital of war veterans
-
Kiev, Ukraine
- Clinical Hospital #15 of the Podilskyi District of the Kyiv City
-
Kyiv, Ukraine, 3037
- "Medbud"
-
Kyiv, Ukraine, 4212
- SMART medical center
-
Kyiv, Ukraine
- Kyiv City Hospital 4
-
Odesa, Ukraine
- Odesa Regional Clinical Hospital, Department of Neurosurgery
-
Poltava, Ukraine
- Medical and diagnostic center of a LLC "Medcontinent", neurology and rehabilitation center
-
Ternopil, Ukraine, 46027
- Ternopil Psycho-Neuro Hospital
-
Uzhhorod, Ukraine
- Regional Clinical Center for Neurosurgery and Neurology
-
-
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85004
- Xenoscience, Inc., 21st Century Neurology
-
-
California
-
West Hollywood, California, États-Unis, 90048
- Regina Berkovich MD, PhD Inc. MS Neurology
-
-
Florida
-
Bradenton, Florida, États-Unis, 34205
- Bradenton Research Center
-
Naples, Florida, États-Unis, 34105
- Collier Neurologic Specialists
-
Ormond Beach, Florida, États-Unis, 32174
- Neurology Associates of Ormond Beach
-
-
Illinois
-
Northbrook, Illinois, États-Unis, 60062
- Consultants in Neurology, Ltd
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Male or female patient (age ≥18 to ≤55 years).
-
Patients with an established diagnosis of MS according to 2017 McDonald Criteria.
-
Patients with RMS comprising of relapsing remitting MS (RRMS) and active secondary progressive MS, both defined according to Lublin criteria 1996 and 2014.
-
Active disease as defined by Lublin 2014 evidenced prior to Screening by:
- At least 2 relapses in the last 24 months before randomization, or
- At least 1 relapse in the last 12 months before randomization, or
- A positive Gd+ MRI scan (brain and/or spine) in the last 12 months prior to randomization.
-
Willingness and ability to comply with the protocol.
-
Written informed consent given prior to any study-related procedure.
Exclusion Criteria:
- Patients with non-active secondary progressive MS and primary progressive MS.
- Any disease other than MS that may better explain the signs and symptoms, including history of complete transverse myelitis.
- Clinical signs or presence of laboratory findings suggestive for neuromyelitis optica (NMO) spectrum disorders or myelin oligodendrocyte glycoprotein (MOG)-IgG-associated encephalomyelitis
- Any active and uncontrolled coexisting autoimmune disease, other than MS (except for type 1 diabetes mellitus and inflammatory bowel disease)
- Use of experimental/investigational drug (with the exception ofCOVID-19 vaccines approved by emergency use authorization) and/or participation in drug clinical studies within 6 months prior to Screening
- Previous or current use of MS treatments lifelong, or within a pre-specified time period.
- Use of the pre-specified concomitant medications.
- Clinically significantly abnormal and pre-specified lab values.
- History of chronic systemic infections within 6 months before the date of informed consent.
- Diagnosis or suspected liver function impairment, which may cause fluctuating liver function tests during this study.
- Known history of nephrolithiasis or underlying condition with a strong association of nephrolithiasis.
- History or clinical diagnosis of gout.
- History or presence of any major medical or psychiatric illness
- Substantial medical condition that could create undue risk to the patient, could affect adherence with the study protocol or could undesirably affect study outcomes
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: IMU-838
IMU-838 (vidofludimus calcium), a small molecule inhibitor of DHODH. Formulation: Tablets with 15 or 30 mg IMU-838 for once daily oral intake in the morning. |
Patients are randomized to IMU-838 or placebo in ratio 1:1
Autres noms:
|
|
Comparateur placebo: Placebo
Matching placebo, as described for the test product, identical number of tablets as given for IMU-838. |
Patients are randomized to IMU-838 or placebo in ratio 1:1
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
To evaluate efficacy of IMU-838 versus placebo regarding time to first relapse
Délai: 72 weeks
|
Survival analysis of time to first relapse, occurred after the start of study treatment administration and before the end of the double-blind period, censored at a maximum of 72 weeks. |
72 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Effect of IMU-838 versus placebo on volume of new T2 lesions
Délai: 72 weeks
|
To evaluate the effect of IMU-838 versus placebo on volume of new T2 lesions. Mean difference between IMU-838- and placebo in changes of the volume of new MRI T2 lesions over 24-weeks of treatment in the double-blind period. |
72 weeks
|
|
Effect of IMU-838 versus placebo on disability progression
Délai: 72 weeks
|
To evaluate the effect of IMU-838 versus placebo on disability progression. Survival analysis of time to 12-week confirmed disability progression, as measured on Expanded Disability Status Scale during the double-blind period, censored at maximum 72-weeks. |
72 weeks
|
|
Effect of IMU-838 versus placebo on cognitive performance
Délai: 72 weeks
|
To evaluate the effect of IMU-838 versus placebo on cognitive performance. Survival analysis of time to confirmed clinically relevant changes on Symbol Digit Modalities Test during the double-blind period, censored at maximum 72-weeks. |
72 weeks
|
|
Effect of IMU-838 versus placebo on whole brain atrophy
Délai: 72 weeks
|
To evaluate the effect of IMU-838 versus placebo on whole brain atrophy. Difference in the mean of the percentage change on the whole brain volume between IMU-838 and placebo during the 72-weeks double-blind period. |
72 weeks
|
|
Safety of IMU-838 versus placebo
Délai: 72 weeks
|
To evaluate safety and tolerability of IMU-838 versus placebo by assessing rates of Treatment Emergent Adverse Events, Adverse Events of Special Interest, Serious Adverse Events, changes in levels of pre-specified laboratory parameters, vital signs and ECG parameters and rates and reasons for study discontinuations. |
72 weeks
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Robert J. Fox, MD, Mellen Center for MS, Neurological Institute, Cleveland Clinic, Ohio
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- P3-IMU-838-RMS-01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .